(Q39632529)

English

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

scientific article published on 4 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study (English)

1 reference

Europe PubMed Central

13 September 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

13 September 2017

Laura Biganzoli

object named as

Laura Biganzoli

14

0 references

object named as

Stefania Gori

11

0 references

object named as

Angelo Di Leo

16

0 references

author name string

Marta Pestrin

1

1 reference

Europe PubMed Central

13 September 2017

Silvia Bessi

2

1 reference

Europe PubMed Central

13 September 2017

Alessandro M Minisini

4

1 reference

Europe PubMed Central

13 September 2017

Giovanna Masci

5

1 reference

Europe PubMed Central

13 September 2017

Nicola Battelli

6

1 reference

Europe PubMed Central

13 September 2017

Alberto Ravaioli

7

1 reference

Europe PubMed Central

13 September 2017

Lorenzo Gianni

8

1 reference

Europe PubMed Central

13 September 2017

Roberta Di Marsico

9

1 reference

Europe PubMed Central

13 September 2017

Carlo Tondini

10

1 reference

Europe PubMed Central

13 September 2017

Charles R Coombes

12

1 reference

Europe PubMed Central

13 September 2017

Justin Stebbing

13

1 reference

Europe PubMed Central

13 September 2017

Marc Buyse

15

1 reference

Europe PubMed Central

13 September 2017

language of work or name

0 references

publication date

4 April 2012

1 reference

Europe PubMed Central

13 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

13 September 2017

134

1 reference

Europe PubMed Central

13 September 2017

1

1 reference

Europe PubMed Central

13 September 2017

283-289

1 reference

Europe PubMed Central

13 September 2017

https://scigraph.springernature.com/pub.10.1007/s10549-012-2045-1

0 references

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Should liver metastases of breast cancer be biopsied to improve treatment choice?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

HER-2 gene amplification can be acquired as breast cancer progresses

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Molecular biomarker analyses using circulating tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

A three-outcome design for phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2045-1

21 January 2018

Identifiers

10.1007/S10549-012-2045-1

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39632529&oldid=1848630752"